Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
Medtronic’s newest closed-loop system posts decent pivotal data, but Insulet and Abbott are waiting in the wings.
For diabetes devices interoperability is key, and partnerships between Insulet, Dexcom and Abbott show that rival groups see the benefits of working together.
The good times continue to roll for big cap device makers, with two companies doubling their market value, and not a single share price fall.
Changes at the FDA have altered the device approval landscape, with the de novo route now the most popular.
Some medtech stocks did decline in 2018, but many more increased in value.
Forming partnerships with a number of players in diabetes technology is the key to growth, according to Ascensia Diabetes Care.